YOLFTbeta
Immunocore Holdings Ltd

Immunocore Holdings Ltd

IMCR · NASDAQ · Healthcare / Biotechnology

29.94USD-0.54 (-1.76%)

Price History

Full chart

Market Stats

Previous Close30.48
Open30.32
Day Range29.76 – 31.00
52-Week Range27.56 – 40.71
Volume270.29K
Market Cap1.58B
P/E (TTM)0.00
Forward P/E23.75
EPS-0.36
Dividend Yield0.00%
Beta0.74
50-Day Avg34.49
200-Day Avg32.37

About

Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Bahija Jallal Ph.D.
  • Employees524
  • Headquarters92 Park Drive, Abingdon, United Kingdom, OX14 4RY, USA
  • Websitehttps://www.immunocore.com

Leadership

  • Dr. Bahija Jallal Ph.D.CEO & Executive Director · b. 1961
  • Mr. Travis Alan Coy M.B.A.CFO, Executive VP & Head of Corporate Development · b. 1980
  • Dr. Kripa Ram Ph.D.Executive VP & Chief Operating Officer · b. 1963
  • Mr. John Goll IIISVP, Finance & Chief Accounting Officer
  • Ms. Annelise Vuidepot Ph.D.Chief Science and Technology Officer & Milton Park Site Head
  • Mr. Sean D. BuckleyVP & Chief Information Officer · b. 1983
  • Mr. Ryan BakerVice President of Investor Relations
  • Ms. Lily Margaret HepworthExecutive VP, General Counsel & Company Secretary · b. 1983
  • Ms. Elizabeth Varki Jobes Esq., J.D.Chief Compliance Officer · b. 1967
  • Mr. Sébastien DesprezVice President of Communications

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue2.04M6.38M11.46M16.46M14.45M23.65M25.67M30.11M27.04M144.23M197.39M247.98M297.57M
Growth (%)-+211.89%+79.63%+43.69%-12.25%+63.74%+8.52%+17.32%-10.19%+433.32%+36.85%+25.63%+20.00%
Cost of Revenue------99.99M74.81M74.13M5.29M820.63K5.54M6.21M
Gross Profit2.04M6.38M11.46M16.46M14.45M23.65M-74.32M-44.70M27.04M138.94M196.57M242.44M291.36M
Gross Margin100.00%100.00%100.00%100.00%100.00%100.00%-289.54%-148.42%100.00%96.33%99.58%97.76%97.91%
Operating Expense6.84M13.69M25.11M48.94M81.97M117.11M44.00M41.50M156.46M181.71M243.77M298.72M325.09M
Operating Income-4.79M-7.31M-13.65M-32.48M-67.53M-93.45M-118.32M-86.19M-129.42M-42.77M-47.20M-56.28M-33.74M
Operating Margin-234.32%-114.61%-119.18%-197.27%-467.43%-395.09%-460.95%-286.22%-478.53%-29.66%-23.91%-22.70%-11.34%
EBITDA-4.36M-6.60M-11.16M-29.79M-64.47M-86.75M-111.56M-82.38M-123.58M-38.35M-40.87M-38.50M387.18K
EBITDA Margin-213.19%-103.42%-97.40%-180.92%-446.26%-366.74%-434.61%-273.57%-456.95%-26.59%-20.71%-15.53%0.13%
Net Income-3.69M-5.59M13.45M-23.13M-49.57M-71.63M-103.93M-74.09M-133.45M-43.46M-43.75M-40.81M-26.42M
Net Income Margin-180.63%-87.70%117.43%-140.50%-343.13%-302.82%-404.89%-246.04%-493.45%-30.13%-22.17%-16.45%-8.88%
R&D6.54M12.20M22.13M46.01M61.16M83.58M99.99M74.81M74.31M84.31M129.42M177.44M204.47M
R&D as % of Total Revenue319.72%191.33%193.11%279.51%423.34%353.32%389.54%248.42%274.77%58.45%65.57%71.55%68.71%
Interest Expense---00842.00K3.80M3.11M5.57M5.41M4.08M18.84M12.17M
Interest Expense % of Total Revenue---0.00%0.00%3.56%14.79%10.32%20.61%3.75%2.07%7.60%4.09%

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets19.58M60.87M273.53M219.08M198.04M195.78M245.94M197.19M407.28M526.76M597.00M1.01B1.07B
Total Liabilities8.44M62.98M59.04M44.10M60.49M139.19M226.37M141.85M175.76M187.86M228.16M648.79M686.24M
Total Equity3.00M-2.10M214.50M174.98M137.55M56.58M19.57M55.35M231.53M338.90M368.84M360.72M381.03M
Cash16.32M50.84M219.98M134.29M83.99M124.39M97.99M176.78M321.06M402.47M442.63M455.73M467.71M
Total Debt----17.17M18.88M78.70M74.47M86.16M81.45M84.03M432.72M436.69M
Net Debt-16.32M-50.84M-219.98M-134.29M-66.82M-105.51M-19.29M-102.31M-234.90M-321.02M-358.59M-23.01M-31.02M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow11.26M39.79M-17.92M-36.90M-61.73M-16.63M-101.38M-60.57M-143.11M-49.21M2.33M26.06M-7.97M
Investing Cash Flow-475.20K-5.68M-5.20M29.42M-9.74M58.01M-4.14M467.00K-1.28M-2.20M-4.29M-355.13M-12.16M
Financing Cash Flow3.00M403.82K158.36M95.96K19.33M101.00K55.13M115.94M288.19M145.44M27.18M343.88M9.20M
Capital Expenditure579.08K2.03M5.79M6.18M17.73M3.54M4.28M3.07M1.39M2.20M4.29M5.17M3.23M
Free Cash Flow10.69M37.76M-23.71M-43.08M-79.46M-20.16M-105.65M-63.65M-144.49M-51.41M-1.97M20.89M-11.20M
Dividends Paid-----0-0000--
FCF to OCF94.86%94.90%132.32%116.75%128.72%121.27%104.22%105.07%100.97%104.48%-84.52%80.15%140.52%
Dividend Paid to FCF-----0.00%-0.00%0.00%0.00%0.00%--

Earnings

Report DateMar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 25, 2021May 12, 2021Aug 11, 2021Nov 10, 2021Mar 3, 2022May 11, 2022Aug 10, 2022Nov 18, 2022Mar 1, 2023May 10, 2023Aug 10, 2023Nov 7, 2023Feb 28, 2024May 8, 2024Aug 8, 2024Nov 6, 2024Feb 26, 2025May 7, 2025Aug 7, 2025Nov 6, 2025Mar 4, 2026May 6, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.000.000.000.000.000.000.00-1.05-0.63-0.92-1.16-82.21-1.05-0.62-0.370.03-0.41-0.40-0.36-21.74-0.38-0.52-0.34-0.16-0.40-0.21-0.24-0.20-0.26-0.01-0.10
EPS Actual-0.01-0.01-0.01-13.67-0.00-0.00-0.00-0.82-1.07-1.04-0.93-91.00-0.46-0.170.14-54.00-0.44-0.370.05-32.22-0.49-0.230.17-0.370.10-0.20-0.00-0.600.25-0.02-
Surprise-------21.90%-69.84%-13.04%19.83%-10.69%56.19%72.58%137.84%-180100.00%-7.32%7.50%113.89%-48.21%-28.95%55.77%150.00%-133.00%125.00%4.76%98.54%-204.57%196.15%-100.00%-
Timing-------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap1.58B
Enterprise Value1.18B
Trailing P/E0.00
Forward P/E23.75
Price / Sales3.67
Price / Book3.87
EPS-0.36
Book Value8.16
Revenue (TTM)430.78M
Gross Profit (TTM)141.59M
EBITDA756.00K
Profit Margin-4.20%
Operating Margin-2.58%
Return on Equity-4.47%
Return on Assets-0.16%
Shares Outstanding51.50M
Shares Float45.83M
Beta0.74
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 17 analystsTarget 62.50
  • Strong Buy
    8
  • Buy
    5
  • Hold
    3
  • Strong Sell
    1

Ownership Breakdown

Institutions
103.14%
Insiders
0.07%
Retail / Other
0.00%

Top Institutional Holders

  • Wellington Management Company LLP
    5.72M11.11%
  • RTW INVESTMENTS, LLC
    4.87M9.46%
  • FMR Inc
    4.83M9.38%
  • PRIMECAP Management Company
    3.64M7.06%
  • Bellevue Group AG
    2.80M5.43%
  • Vestal Point Capital LP
    2.77M5.37%
  • TANG CAPITAL MANAGEMENT LLC
    2.65M5.14%
  • T. Rowe Price Investment Management,Inc.
    1.89M3.67%
  • Two Sigma Investments LLC
    1.65M3.20%
  • Millennium Management LLC
    1.60M3.10%
  • Caligan Partners LP
    1.38M2.68%
  • Kynam Capital Management, LP
    1.38M2.67%
  • Bvf Inc
    1.29M2.51%
  • Armistice Capital, LLC
    1.19M2.31%
  • Point72 Asset Management, L.P.
    1.10M2.14%
  • Fiera Capital Corporation
    1.08M2.10%
  • Trails Edge Capital Partners, LP
    1.06M2.06%

Top Fund Holders

  • Vanguard Health Care Inv
    4.25M8.25%
  • Vanguard Capital Opportunity Inv
    2.34M4.54%
  • PRIMECAP Odyssey Aggressive Growth
    1.11M2.16%